Management of Thrombocytopenia and Anemia in Anticoagulated Patients

Critical First Steps

The FDA recommends discontinuing enoxaparin immediately if platelet count falls below 100,000/mm³, and the patient is already below this threshold at 77 × 10⁹/L, with severe anemia (Hgb 72 g/L) representing a significant bleeding risk that contraindicates continued anticoagulation, according to the American College of Cardiology guidelines 1
Urgent heparin-induced thrombocytopenia (HIT) workup is necessary, as enoxaparin can cause HIT with thrombosis, which paradoxically increases both bleeding and clotting risk, as stated by the American Society of Hematology 2
Transfuse blood products, including red blood cells to target Hgb >80 g/L given the severe anemia, and platelet transfusion if active bleeding is present or invasive procedures are needed, as recommended by the American Association of Blood Banks 1, 3

Assess for active bleeding sources, including checking stool for occult blood, examining skin for petechiae/purpura, and assessing for mucosal bleeding, as suggested by the International Society on Thrombosis and Haemostasis 1
Obtain coagulation studies (PT/INR, aPTT, fibrinogen, D-dimer) to rule out disseminated intravascular coagulation, according to the College of American Pathologists 2
Evaluate etiology of cytopenias, including complete blood count with differential and peripheral blood smear, direct Coombs test, and bone marrow biopsy if unexplained, as recommended by the American Society of Clinical Oncology 1, 3

The International Society on Thrombosis and Haemostasis provides clear platelet count-based thresholds for restarting anticoagulation, including resuming full therapeutic-dose enoxaparin without platelet transfusion support at platelets ≥50 × 10⁹/L, as stated by the American College of Chest Physicians 1, 5
If HIT is confirmed, never restart any heparin product, and switch to direct thrombin inhibitors like argatroban or bivalirudin instead, as recommended by the American Heart Association 2, 4

If anticoagulation is absolutely necessary before platelets recover, consider reduced-dose low molecular weight heparin (LMWH) with platelet transfusion support only for high-risk thrombosis, as suggested by the American College of Cardiology 1, 5, 4

Do not continue enoxaparin based solely on "needing anticoagulation", as the bleeding risk far outweighs thrombosis risk in most clinical scenarios, according to the American Society of Hematology 1
Do not add antiplatelet agents, as they dramatically increase bleeding risk, as stated by the American Heart Association 4
Do not delay transfusion while waiting for diagnostic workup, as Grade 3 anemia requires immediate transfusion support, as recommended by the American Association of Blood Banks 3